Casopitant: a new warrior in the antiemetic crusade

Bibliography

• Khojasteh A, Sartiano G, Efstathios T, et al. Ondansetron (GR 38032F) for prevention of high-dose cisplatin. Oncology Digest 1991;2:24-5
   Google Scholar
• Ettinger DS, Bierman PJ, Bradbury B, et al. Antiemesis: clinical practice guidelines in oncology. J Natl Compr Canc Netw 2007;5:12-33
   PubMedGoogle Scholar
• Lyman GH. Impact of chemotherapy dose intensity on cancer patient outcomes. J Natl Comp Canc Netw 2009;9:99-108
   Google Scholar
• Grunberg S, Deuson RR, Mavros P. Incidence of chemotherapy-induced nausea and emesis after modern antiemetics: perception versus reality. Cancer 2004;2(Suppl 1):1-12
   Google Scholar
• Grunberg SM, Osoba D, Hesketh PJ, et al. Evaluation of new antiemetic agents and definition of antineoplastic agents emetogenicity: an update. Support Care Cancer 2005;13:80-4
   PubMed Web of Science ®Google Scholar
• Hesketh PJ, Kris MG, Grunberg SM, et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 1997;15:103-9
   PubMed Web of Science ®Google Scholar
• Hesketh PJ, Van Belle S, Aapro M. Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor anagonists. Eur J Cancer 2003;39:1074-80
   PubMed Web of Science ®Google Scholar
• Navari RM, Reinhardt RR, Gralla RJ, et al. Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group. N Engl J Med 1999;34(3):190-5
   Google Scholar
• Otsuka M, Yoshioka K. Neurotransmitter functions of mammalian tachykinins. Physiol Rev 1993;73(2):229-308
   PubMed Web of Science ®Google Scholar
• Navari RM. Casopitant, a neurokinin-1 receptor antagonist with antiemetic and antinausea activities. Curr Opin Investig Drugs 2008;9(7):774-85
   PubMed Web of Science ®Google Scholar
• Hietala J, Nyman MJ, Eskola O, et al. Visualization and qualification of neurokinin-1 (NK-1) receptors in the human brain. Mol Imaging Biol 2005 DOI: 10.1007/s11307-3005-7001-6
   PubMedGoogle Scholar
• Heargraves R. Imaging substance P receptors (NK-1) in the living human brain using positron emission tomography. J Clin Psychiatry 2002;63(Suppl 11):18-24
   Google Scholar
• Lohr L. Chemotherapy-induced nausea and vomiting. Cancer J 2008;14(2):85-93
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline scientific files: compound GW679769, casopitant, Aug6, 2007
   Google Scholar
• Dam T, Quirion R. Pharmacological characterization and autoradiographic localization of substance P receptors in guinea pig brain. Peptides 1986;7(5):855-64
   PubMedGoogle Scholar
• A study of healthy subjects to assess the effect of ketoconazole and the way the body will react to casopitant [GW679769]. Clinical Trials.gov. NCT00404378 . August 29, 2008
   Google Scholar
• A study of healthy subjects to assess how dosing of rifampin affects what the body does to a dose of GW679769 (Casopitant). Clinical Trials.gov. NCT00405080. August 29, 2008
   Google Scholar
• Arpornwirat W, Albert I, Hansen VL, et al. Multicenter, randomized, double-blind, ondansetron (ond)-controlled, dose-ranging, parallel group tiral of the neurokinin-1 receptor antagonist (NK-1 RA) casopitant mesylate for chemotherapy-induced nausea/vomiting (CONV) in patients (pts) receiving moderately emetogenic chemotherapy (MEC). J Clin Oncol 2006;24(18S):8512
   Google Scholar
• Blum R, Adams LM, Johnson BM, et al. Effect of casopitant, a novel neurokini-1 (NK-1) receptor antagonist for prevention of chemotherapy induced nausea and vomiting (CINV), on the pharmacokinetics (PK) and pharmacodynamics (PD) of steady-state warfarin [abstract 20587]. J Clin Oncol 2008 ASCO Annual Meeting Proceedings 26:15S (May 20 Supplement) 2008: 20587
   Google Scholar
• Macapinlac M, Biggs DD, Johnson BM, et al. Interim results of an open-label, repeat dose, randomized, crossover study to investigate safety and potential pharmacokinetic interactions between the oral neurokinin-1 receptor antagonist casopitant mesylate and intravenous cyclophosphamide in cancer patients [abstact 6088]. 29th Annual San Antonio Breast Cancer Symposium (SABCS) San Antonio, USA; 14 – 16 Dec, 2006
   Google Scholar
• The effects of GW679769 (Casopitant) on the pharmacokinetics of docetaxel in subjects with cancer. Clinical Trials.gov. NCT00440128. August 29, 2008
   Google Scholar
• A study to assess the safety and interaction between casopitant and ketoconazole when taken by healthy adults. Clinical Trials.gov, NCT00460707. August 29, 2008
   Google Scholar
• The pharmacokinetic interaction between oral casopitant and oral dolasetron, granisetron or rosiglitazone in subjects. Clinical Trials.gov. NCT00511823. August 29, 2008
   Google Scholar
• Lates C, Adams L, Lu E, et al. Effect of casopitant, a novel NK-1 receptor antagonist, on the pharmacokinetics of co-administered ondansetron and dexamethasone. 2008 International Symposium of Supportive Care in Cancer of the Multinational Association of Supportive Care of Cancer (MASCC) held jointly with the International Society of Oral Oncology (ISOO) Huston, USA; 26 – 28 June, 2008:01-012
   Google Scholar
• Observational pharmacokinetic study of GW679769 in subjects with renal impairment. Clinical Trials.gov. NCT00358813. August 29, 2008
   Google Scholar
• Observational study evaluating the processing or breakdown of GW679769 in subjects with hepatic impairment. Clinical Trials.gov. NCT00359177. August 29, 2008
   Google Scholar
• GlaxoSmithKline plc. GSK: Product development pipeline. Company World Wide Web Site. February 29, 2008
   Google Scholar
• Herrstedt J, Arpornwirat W, Albert I, et al. Safety and efficacy of the novel antiemetic neurokinin-1 (NK1) receptor antagonist, casopitant, in women with breast cancer (BC) receiving moderately emetogenic chemotherapy (MEC)-subgroup analysis from a randomized, double-blind, placebo-controlled phase II trial [abstract 492]. 6th European Breast Cancer Conference (EBCC6) Berlin, Germany; 15 – 19 Apr, 2008
   Google Scholar
• Albert I, Arpornwirat W, Hansen VL, et al. Efficacy of the neurokin-1 antagonist casopitant mesylate in CINV with taxane- and non-taxane-based, moderately emetogenic chemotherapy (MEC): subgroup analysis from a randomized, double-blind, placebo-controlled phase II trial. 31st Congress of the European Society for Medical Oncology (ESMO) Istanbul, Turkey; 29 Sep – 3 Oct, 2006:1051P
   Google Scholar
• Hansen VL, Gabrail N, Levin J, et al. Antiemetic efficacy of the novel neurokinin-1 (NK-1) antagonist, casopitant, in patients with GI cancers receiving oxaliplatin-based chemotherapy (OX): subgroup analysis from a randomized, double-blind, placebo-controlled phase II trial. 2008 Gastrointestinal Cancers Symposium (ASCO) Orlando, USA; 25 – 27 Jan, 2008:359
   Google Scholar
• Rolski J, Ramlau R, Dediu M, et al. Phase II trial of the neurokinin-1 antagonist casopitant mesylate for the prevention of chemotherapy-induced nausea/vomiting (CINV) in cancer patients (PTS) receiving highly emetic chemotherapy (HEC): Subgroup analysis by cisplatin dose [abstract 1052P]. Ann Onc 2006;17: ix286-ix307
   Google Scholar
• Grunberg SM, Aziz Z, Shaharyar A, et al. Phase III results of a novel neurokin-1 (NK-1) receptor antagonist, casopitant: single oral and 3-day oral dosing regimens for chemotherapy-induced nausea and vomiting (CINV) in patients (Pts) receiving moderately emetogenic chemotherapy (MEC). 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) Chicago, USA; 30 May – 3 Jun, 2008:9540
   Google Scholar
• Herrstedt J, Grunbert S, Rolski J, et al. Phase III results of a novel neurokin-1 (NK-1) receptor antagonist, casopitant: single oral and 3-day oral dosing regimens for chemotherapy-induced nausea and vomiting (CINV) in patients (Pts) receiving highly emetogenic chemotherapy (HEC). 44th Annual Meeting of the American Society of Clinical Oncology (ASCO); 2008:9549
   Google Scholar
• Singla N, Chung F, Singla S, et al. Efficacy of oral casopitant mesylate, a novel neurokinin-1 receptor antagonist, with intravenous ondansetron HCL in the prevention of postoperative nausea and vomiting (PONV) in high-risk patients. Euroanaesthesia 2006 – 4th Joint Meeting of the European Society of Anaesthesiologists, European Academy of Anaesthesiology and Confederation of National Societies of Anaesthesiologists Aberdeen, UK; 19 – 22 Sep,2006:A-614
   Google Scholar
• Chung F, Singla N, Singla S. Casopitant for preventing postoperative vomiting in patients receiving opioids: pooled data analysis. 57th Annual Meeting of the American Society of Anesthesiologists (ASA) Madrid, Spain; 14 Oct, 2006:A206
   Google Scholar
• Announcements: GlaxoSmithKline. New drug application submitted for casopitant in CINV. Oncology 2008;22(5)
   Google Scholar
• Hudson N. GSK oncology pipeline update fails to impress investors. APM News 18/06/2007; 7103- Cancer
   Google Scholar
• King A. Comparison of anti-emetic and peri-emetic behaviors of NK-1 receptor antagonists GW679769 and aprepitant in the ferret. 17th International Symposium of Supportive Care in Cancer of the Multinational Association of Supportive Care in Caner/International Society of Oral Oncology (MASCC) Geneva, Switzerland; 30 Jun – 2 Jul, 2005:04-031
   Google Scholar
• Dala M, Guckert M, Arondekar B, et al. Favourable patient reported nausea and quality of life observed with casopitant, a novel neurokinin-1 (NK-1) receptor antagonist, in patients (Pts) receiving highly emetogenic chemotherapy (HEC). Ann Oncol 2008;19(Suppl 8):890P
   Google Scholar
• Reddy GK, Gralla RJ, Hesketh PJ. Novel neurokinin-1 antagonists as antiemetics for the treatment of chemotherapy-induced emesis. Supp Canc Ther 2006;3(6):140-2
   PubMedGoogle Scholar
• Bakalar N. Cancer on the rise. The New York Times. December 22, 2008
   Google Scholar